Johnson & Johnson (JNJ)
3 No-Brainer Dividend Growth Stocks to Buy in June
With the rate environment stabilizing in mid-2026, income investors are circling back to a familiar playbook: own the businesses that have raised payouts through every cycle in living memory.
I Would Rebuild My Portfolio With Just These 3 Stocks If I Lost Everything Tomorrow
I keep buying NVIDIA, Eli Lilly, and Johnson & Johnson, and if a fire took my brokerage statement to zero tomorrow, those are the three tickers I would start typing in again on day one.
Got $1,000? 1 Healthcare King to Buy and Never Sell That Is Safer Than a Treasury Bond
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is a rare long-duration compounder because it is the rare equity whose credit quality, dividend record, and demand profile collectively rival a sovereign bond while still compounding capital.
Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal
Joaquin Duato said finding a cure for certain cancers and turning others into chronic diseases is an achievable target for the coming decade.
Johnson & Johnson (JNJ) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Johnson & Johnson (JNJ) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
J&J to Expand Cancer Pipeline With $1B Firefly Bio Acquisition
JNJ is set to acquire Firefly Bio for $1 billion in cash, adding its Firelink DAC platform and advancing efforts in KRAS-driven cancer treatments.
JNJ and AZN Face Patent Headwinds: Which Stock Looks Stronger Now?
J&J's diversified healthcare business and growth outlook help it stand out against AstraZeneca despite patent and legal challenges.
Will Johnson & Johnson Stock Hit $300 This Year?
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) has rallied 13.73% year to date and 55.27% over the past year, fueled by oncology blockbusters and a MedTech franchise hitting on every cylinder.
J&J beats lawsuit alleging that talc caused three women's cancer
A Los Angeles jury on Friday sided with Johnson & Johnson in a lawsuit by the families of three women who alleged that the company's talc products caused ovarian cancer, finding that J&J was not negligent when selling cosmetic talc products.
Can JNJ Sustain Growth Amid Patent, Legal and China Risks?
J&J faces Stelara erosion, China MedTech pressure and talc litigation, but targets $100B revenues and faster growth in 2026.
Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Johnson & Johnson (JNJ) closed at $228.17, marking a +2.21% move from the previous day.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
